![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Biogen Begins Phase 3 Trial Evaluating Lupus Therapy
Biogen Begins Phase 3 Trial Evaluating Lupus Therapy
![Biogen-logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Biogen-logo.gif?t=1595365104&width=430)
June 21, 2021
Biogen has launched a phase 3 trial of its monoclonal antibody, BIIB059, a potential blockbuster that has shown promise for treating individuals suffering from lupus, a chronic and debilitating autoimmune disease.
The trial plans to enroll 540 adults across 135 global sites to assess the antibody vs. a placebo over 52 weeks, the company said.
Lupus, which affects multiple organs and is linked with a greater risk of death from infection and heart disease, among other conditions, afflicts an estimated 4 million individuals worldwide.
Upcoming Events
-
21Oct